Ascletis' oral GLP-1 ASC30 cut HbA1c by 1.7% in a Phase II type 2 diabetes trial. Read the full results and what they mean ...
MIT's soft snake-inspired robot crawled 2 meters through pig small intestine in 11 minutes. Read how this early study could ...
Vanda's Nereus (tradipitant) cut semaglutide-induced vomiting to 43% vs 58.5% on placebo in Phase III. Read the full data and ...
FDA proposes streamlined approvals for personalized gene editing as CMS expands therapy access model
FDA draft guidance lets sponsors add patient-specific variants to one BLA for personalized genome editing therapies. Read on for CMS access details.
UCLA researchers show engineered CAR NK cells selectively kill HIV-infected cells and delay viral rebound after ART stops in ...
Atlas Bio raises $12.5M to test drugs on virtual patients, targeting the 70% drug failure rate. Read how it works and why ...
Eli Lilly licensed the SpeechDx speech-biomarker dataset from the Alzheimer's Drug Discovery Foundation to study speech in Alzheimer's research. Read more.
Barcelona's Allox closes $10.5M seed round to scale its allosteric drug discovery platform and advance protein-protein ...
Orphan Therapeutics Accelerator licenses OTXL-101, an investigational AAV liver-targeted gene therapy for ornithine transcarbamylase deficiency. Read more.
Novartis takes a $1.9B delgocitinib writedown after a Duchenne failure as remibrutinib nears FDA filing in MS. Read the full ...
LYNK Pharmaceutical's zemprocitinib sustained ACR20 response above 91% in Phase III rheumatoid arthritis trial. Discover the full long-term results and ...
Nxera exercises its option for exclusive rights to Idorsia's lucerastat for Fabry disease in Japan and Asia ex-China. Read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results